Posts Tagged ‘Prescription Overutilization’

PBM Consulting – Top 15 Therapeutic Classes

Monday, July 26th, 2010

IMS Health data for 2009 creates an interesting picture of global drug sales and growth in specific therapeutic classes. WBC (wbcbaltimore.com) has taken a look and found that the global picture is clearly different when compared to  U.S. pharmacy benefit plan sponsor drug spend.  In the U.S., antipsychotics were the leading therapeutic class with $14.6 billion in sales. Antilipididemics (like Lipitor, Crestor, simvastatin, etc.) with $14.3 billion is number two; acid reflux (Nexium, Prevacid, etc.) with $13.6 billion in sales comes in at number three; and antidepressants (Cymbalta, Effexor, etc.) holds down the number four spot with $9.9 billion in sales. Surprisingly, oncology agents, while number one globally in sales, ranks number six in the U.S.

Here are the global sales and growth numbers for 2009:

Drug Class

2009 Sales (billions)

Annual Growth

Oncologics

$52.37

8.8%

Lipid Regulators $35.28 4.9%
Respiratory Agents $33.59 11.0%
Antidiabetics $30.40 13.4%
Anti-ulcerants $29.61 0.6%
Angiotensin II Antagonists $25.20 11.4%
Antipsychotics $23.24 4.6%
Antidepressants $19.41 -1.3%
Autoimmune Agents $17.96 18.0%
Platelet Aggr. Inhibitors $14.60 9.0%
HIV Antivirals $13.75 14.9%
Anti-epileptics $12.99 -19.8%
Narcotic analgesics $11.23 8.6%
Non-narcotic analgesics $11.17 7.3%
Erthropoietins $10.80 -4.1%

Data source: IMS Health

Reducing Healthcare Costs – Wasted Dollars

Tuesday, December 8th, 2009

A somewhat surprising report was released by Thomson Reuters regarding the wasteful spending practices within the American healthcare system. Not that system inefficiencies, unnecessary testing and good old-fashioned fraud should come as any surprise to those who follow this stuff, but it was the degree that caught my eye.

Losses in DollarsTheir conclusion is that big dollars fly out the window to the tune of an estimated $700 billion annually.  That’s about 1/3 of our nations’ annual healthcare tab!

Here’s what they found:

Fraud, which finds a happy home in many Medicare and Medicaid billing fiascoes, accounts for between $125 billion to $175 billion each year.

Administrative Inefficiency accounts for between $100 billion - $150 billion.  This is the endless stream of paperwork that an EMR is suppose to help.

Provider Errors create mistakes that chalk up another $75 billion to $100 billion.

Unnecessary Care is my favorite and one that made me look twice.  This is the one that providers will over-prescribe or over-test in order to limit their malpractice risk. Contrary to what the tort lawyers say, this study pegged this expense at a whopping $250 billion to $325 billion annually! This is by far the highest estimate attributed to this practice that I’ve seen.

Preventable Conditions is the second category that caught my attention. Long reported as representing anywhere from 25 – 50% of total medical spending, this study allocated a much more modest $25 billion to $50 billion. Let’s hear from the Wellness industry on this one.

Lack of Care Coordination was identified as the last major category. This is characterized by inefficient communications between providers that result in duplicating tests and less than “best practices” treatment. The price tag: another $25 billion to $50 billion per year.